Trial · NCT03536143
Adverse events28
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 28
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Application site pruritus | General disorders | All Participants (Topical Beremagene Geperpavec (B-VEC), and Placebo) | 2 | 12 | 2 |
| other | Application site bruise | General disorders | All Participants (Topical Beremagene Geperpavec (B-VEC), and Placebo) | 1 | 12 | 1 |
| other | Application site erythema | General disorders | All Participants (Topical Beremagene Geperpavec (B-VEC), and Placebo) | 1 | 12 | 1 |
| other | Application site rash | General disorders | All Participants (Topical Beremagene Geperpavec (B-VEC), and Placebo) | 1 | 12 | 1 |
| other | Fatigue | General disorders | All Participants (Topical Beremagene Geperpavec (B-VEC), and Placebo) | 1 | 12 | 1 |
| other | Feeling cold | General disorders | All Participants (Topical Beremagene Geperpavec (B-VEC), and Placebo) | 1 | 12 | 1 |
| other | Injection site erythema | General disorders | All Participants (Topical Beremagene Geperpavec (B-VEC), and Placebo) | 1 | 12 | 2 |
| other | Injection site pain | General disorders | All Participants (Topical Beremagene Geperpavec (B-VEC), and Placebo) | 1 | 12 | 3 |
| other | Injection site swelling | General disorders | All Participants (Topical Beremagene Geperpavec (B-VEC), and Placebo) | 1 | 12 | 1 |
| other | Pyrexia | General disorders | All Participants (Topical Beremagene Geperpavec (B-VEC), and Placebo) | 1 | 12 | 1 |
| other | Bacterial vaginosis | Infections and infestations | All Participants (Topical Beremagene Geperpavec (B-VEC), and Placebo) | 1 | 12 | 1 |
| other | Pharyngitis streptococcal | Infections and infestations | All Participants (Topical Beremagene Geperpavec (B-VEC), and Placebo) | 1 | 12 | 1 |
| other | Purulent discharge | Infections and infestations | All Participants (Topical Beremagene Geperpavec (B-VEC), and Placebo) | 1 | 12 | 2 |
| other | Wound infection pseuomonas | Infections and infestations | All Participants (Topical Beremagene Geperpavec (B-VEC), and Placebo) | 1 | 12 | 1 |
| other | Erythema | Skin and subcutaneous tissue disorders | All Participants (Topical Beremagene Geperpavec (B-VEC), and Placebo) | 1 | 12 | 1 |
| other | Pruritis | Skin and subcutaneous tissue disorders | All Participants (Topical Beremagene Geperpavec (B-VEC), and Placebo) | 1 | 12 | 1 |
| other | Rash | Skin and subcutaneous tissue disorders | All Participants (Topical Beremagene Geperpavec (B-VEC), and Placebo) | 1 | 12 | 2 |
| other | Rash generalised | Skin and subcutaneous tissue disorders | All Participants (Topical Beremagene Geperpavec (B-VEC), and Placebo) | 1 | 12 | 1 |
| other | Diarrhoea | Gastrointestinal disorders | All Participants (Topical Beremagene Geperpavec (B-VEC), and Placebo) | 1 | 12 | 1 |
| other | Nausea | Gastrointestinal disorders | All Participants (Topical Beremagene Geperpavec (B-VEC), and Placebo) | 1 | 12 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03536143/events